

DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C.F., Armstrong, L., Goldman, M.P., Lance, L.L., Alvarez, W., dkk., 2009. Drug Information Handbook, 17th ed. Lexi-Comp for The American Pharmacists.
- American Society of Health-System Pharmacists, 2021. ASHP® Injectable Drug Information™: A Comprehensive Guide to Compatibility and Stability. ASHP.
- Barreto, J. N., McCullough, K. B., Ice, L. L. dan Smith, J. A. 2014. Antineoplastic Agents and The Associated Myelosuppressive Effects: A Review. *Journal of Pharmacy Practice*. 27(5): 440–446.
- BC Cancer. 2020. Clinical Pharmacy Guide : Cancer Drug Treatment Assessment and Review. 5 : 1-15.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., dan Jemal, A., 2018. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 68: 394–424.
- Bryer E, Henry D. 2018. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. *International Journal of Clinical Transfusion Medicine*. 6:21-31
- Burger, R. 2013. Impact of Interleukin-6 in Hematological Malignancies. *Transfusion Medicine and Hemotherapy*. 40(5): 336-343
- Cannavale, K., Xu, H, Xu, L., Sattayapiwat, O., Rodriguez, R., Bohac, C., dkk., 2019. Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma. *The Permanente Journal*, 23 :18-252.
- Cerny, T., Borisch, B., Introna, M., Johnson, P., dan Rose, A.L., 2002. Mechanism of Action of Rituximab: Anti-Cancer Drugs, 13: S3–S10.
- Chan, A., Tan, C.J., dan Sessions, J., 2020. Lymphomas, dalam: DiPiro, Joseph T., Yee, Gary C., Posey, L.Michael., Haines, Stuart T, Nolin, Thomas D., Dan Ellingrod, Vicki L. *Pharmacotherapy: A Pathophysiologic Approach*. MC Graw Hill, hal. 6651–6736.
- Chuang, S.-S., Chen, S.-W., Chang, S.T., dan Kuo, Y.T., 2017. Lymphoma in Taiwan: Review of 1347 Neoplasms from A Single Institution according to The 2016 Revision of The World Health Organization Classification. *Journal of the Formosan Medical Association*, 116: 620–625.
- Cipolle, R.J., Morley, P.C., dan Strand, L.M., 2012. *Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services*, 3th ed. McGraw-Hill Education, New York.
- Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., dkk., 2013. Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and

- Prednisolone in Patients with Newly Diagnosed Diffuse Large B-Cell Non-Hodgkin Lymphoma: A Phase 3 Comparison of Dose Intensification with 14-Day versus 21-Day Cycles. *The Lancet*, 381: 1817–1826.
- Dahlan, S.M. 2014. *Statistik untuk Kedokteran dan Kesehatan : Deskriptif, Bivariat dan Multivariat Seri 1 Edisi 6*. Epidemiologi Indonesia, Jakarta.
- Dhyanti, A.L., 2020. *Anemia Among B-Cell Non-Hodgkin's Lymphoma Patients in Dr. Sardjito Hospital: Correlation with International Prognostic Index (IPI) Score Components*. Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Tesis, Universitas Gadjah Mada, Yogyakarta.
- Diumenjo, M.C., Abriata, G., Forman, D., dan Sierra, M.S., 2016. The Burden of Non-Hodgkin Lymphoma in Central and South America. *Cancer Epidemiology*, 44: S168–S177.
- Dumontet C, Mounier N, Munck JN, dkk. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. *Br J Haematol*. 2002; 118: 210 – 17.
- Fadhliya, F., Kurnia, B., Setiani, L., Karnita, Y., Juniar, J., dan Berliananda, I., 2020. Characteristics of Non-Hodgkin Lymphoma Patients in Otorhinolaryngology-HNS Department Zainoel Abidin General Hospital Banda Aceh. *Oto Rhino Laryngologica Indonesiana*, 50: 46.
- Farmanfarma, K.K., Kiasara, S.H., Hassanipour, S., dan Salehiniya, H., 2020. Non-Hodgkin's lymphoma in the world: an epidemiological review. *World Cancer Research Journal*, 7: 1–6.
- Gao, G., Liang, X., Jiang, J., Zhou, X., Huang, R., Chu, Z., dkk., 2010. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. *Acta Oncologica*, 49: 3–12.
- Gaspar, B.L., Sharma, P., dan Das, R., 2015. Anemia in malignancies: Pathogenetic and diagnostic considerations. *Hematology*, 20: 18–25.
- Gilreath, J.A., Stenehjem, D.D. dan Rodgers, G.M. 2014. Diagnosis and treatment of cancer-related anemia. *Am. J. Hematol.* 89: 203-212.
- Horesh, N., & Horowitz, N. A. 2014. Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior and Therapy. *Rambam Maimonides medical journal*. 5(4) : 1-8
- Hu, X., Zeng, M., Yang, S., Liang, X., Ding, S., Guo, L., Li, S., Wen, S., 2017. Efficacy of Rituximab Combined with CHOP for Treating Patients with Diffuse Large B-Cell Lymphoma. *Medicine*. 96 (45) : 1-4.
- Idris M, Shah SH, Fareed J, dkk. An experience with sixty cases of haematological malignancies; a clinicohaematological correlation. *J Ayub Med Coll Abbottabad*. 2004; 16: 51-4.
- Istiadi, H., Sadhana, U., Puspasari, D., Miranti, I.P., Karlowee, V., Listiana, D.E., dkk., 2021. Role of Cell-Origin Profiling Using Immunohistochemistry to

- Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia. *Yonago Acta Medica*, 64: 200–206.
- Kementerian Kesehatan RI, 2015. Data dan Kondisi Penyakit Limfoma di Indonesia. Pusat Data dan Informasi Kementerian Kesehatan RI, 1–6.
- Komite Penanggulangan Kanker Nasional, 2015. Panduan Penatalaksanaan Limfoma Non Hodgkin. Kementerian Kesehatan Republik Indonesia.
- Kusulistyo, F., Suprihati, S., Yusmawan, W., Antono, D., Budiarti, R., Farokah, F., dkk., 2021. Pengaruh Suplementasi Koenzim Q10 terhadap Kadar Laktat Dehidrogenase Penderita Limfoma Non-Hodgkin yang Menjalani Kemoterapi di RSUP Dr.Kariadi Semarang. *Medica Hospitalia : Journal of Clinical Medicine*, 8: 207–212.
- Lamar, Z.S., 2016. The Role of Glucocorticoids in the Treatment of Non-Hodgkin Lymphoma. *Annals of Hematology and Oncology* 3(7) 1103: 5.
- Lemeshow, S., Hosmer Jr, D.W., Klar, J., dan Lwanga, S.K., 1990. Adequacy of Sample Size in Health Studies. *Biometrics*. Biometrics.
- Ludwig, H., Aapro, M., Bokemeyer, C., Glaspy, J., Hedenus, M., Littlewood, T. J., Österborg, A., Rzychon, B., Mitchell, D., & Beguin, Y. 2014. A European Patient Record Study on Diagnosis and Treatment of Chemotherapy-induced anaemia. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 22(8), 2197–2206.
- Mathur, P., Sathishkumar, K., Chaturvedi, M., Das, P., Sudarshan, K.L., Santhappan, S., dkk., 2020. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. *JCO Global Oncology*, 1063–1075.
- Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., dan Macciò, A. 2018. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Frontiers in physiology*, 9, 1294.
- Momotow, J., Borchmann, S., Eichenauer, D.A., Engert, A., dan Sasse, S., 2021. Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. *Journal of Clinical Medicine*, 10: 1125.
- Nair, Reena, Kakroo, A., Bapna, A., Gogia, A., Vora, A., Pathak, A., dkk., 2018. Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. *Indian Journal of Hematology and Blood Transfusion*, 34: 398–421.
- National Comprehensive Cancer Network (NCCN), 2018. NCCN Clinical Practice Guideline in Oncology Cancer and Chemotherapy Induced Anemia. NCCN.
- National Comprehensive Cancer Network, 2021. NCCN Clinical Practice Guidelines B-Cell Lymphomas. NCCN.

- National Guideline Alliance dan National Institute for Health and Care Excellence, 2016. Non-Hodgkin's Lymphoma: Diagnosis and Management.
- Ninkovic S. dan Lambert J. 2017. Non-Hodgkin lymphoma. *Medicine*, 45(5):297–304.
- Nogai, H., Dörken, B., dan Lenz, G., 2011. Pathogenesis of Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology*, 29: 1803–1811.
- Painschab, M.S., Kohler, R., Kimani, S., Mhango, W., Kaimila, B., Zuze, T., dkk., 2021. Comparison of Best Supportive Care, CHOP, or R-CHOP for Treatment of Diffuse Large B-Cell Lymphoma in Malawi: A Cost-Effectiveness Analysis. *The Lancet Global Health*, 9: e1305–e1313.
- Parastuti, N.P.Y.R. dan Rena, N.M.R.A., 2019. Gambaran Klinis Efek Samping Kemoterapi pada Pasien Limfoma Maligna yang Dirawat di RSUP Sanglah Denpasar Periode Januari 2015-Agustus 2016. *Jurnal Medika Udayana*, 9 (1): 27–32.
- Perry, A.M., Diebold, J., Nathwani, B.N., MacLennan, K.A., Muller-Hermelink, H.K., Bast, M., dkk., 2016. Non-Hodgkin Lymphoma in The Developing World: Review of 4539 Cases from The International Non-Hodgkin Lymphoma Classification Project. *Haematologica*, 101: 1244–1250.
- Plosker, G. L., dan Figgitt, D. P. 2003. Rituximab: A Review Of Its Use In Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukaemia. *Drugs*. 63(8): 803–843.
- Primastari E, Hernowo BS, Dewayani BM, 2020. Clinicopathological Profile of Low-Grade B Cell Non-Hodgkin Lymphoma in Tertiary Health Care in West Java Indonesia. *Journal of Drug Delivery and Therapeutics*, 10(6-s):89-91.
- Reksodiputro, A. H. 2015. Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients in Indonesia. *J Blood Disorders. Transf* 6 (2):1-5
- Salma, R.S., Sedana, M.P., dan Yudho, S.U., 2018. CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya. *Biomolecular and Health Science Journal*, 1: 93.
- Sarfati, D., Koczwara, B., dan Jackson, C., 2016. The impact of comorbidity on cancer and its treatment: Cancer and Comorbidity. *CA: A Cancer Journal for Clinicians*, 66: 337–350.
- Shanbhag, S. dan Ambinder, R.F., 2018. Hodgkin lymphoma: A Review and Update on Recent Progress: Current Progress in Hodgkin Lymphoma. *CA: A Cancer Journal for Clinicians*, 68: 116–132.
- Stauder, R., Valent, P., dan Theurl, I. 2018. Anemia at older age: etiologies, clinical implications, and management. *Blood*, 131(5): 505–514.

- Tariq, A., Aziz, M. T., Mehmood, Y., Asghar, S. A., Khurshid, A. 2018. Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas. *Asian Pacific journal of cancer prevention* : APJCP, 19(5): 1181–1184.
- Tisi, M.C., Bozzoli, V., Giachelia, M., Massini, G., Ricerca, B.M., Maiolo, E., dkk. 2014. Anemia in diffuse large B-Cell Non-Hodgkin's Lymphoma: The Role of Interleukin-6, Heparin and Erythropoietin, *Leukemia and Lymphoma*, 55:270–275.
- Wang, Y., Probin, V., dan Zhou, D. 2006. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. *Current cancer therapy reviews*. 2(3): 271–279.
- Winarto, D., Rena, N.M.R.A., Adnyana, W.L., Dharmayuda, T.G., Suega, K., dan Bakta, I.M., 2018. Kadar Hemoglobin Awal Sebagai Faktor Prognostik Penderita Limfoma Non-Hodgkin (LNH) yang Menjalani Kemoterapi. *Jurnal Penyakit Dalam Udayana*, 2: 38–43.
- World Health Organization, 2011. Haemoglobin Concentrations for The Diagnosis of Anaemia and Assessment of Severity, WHO.
- Yamamoto, M., Suzuki, I., Saitou, K. 2020 . Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. *J Cancer Res Clin Oncol*. 146 : 2995–3002.
- Yaniari, R., Ashariati, A. dan Bintoro, U.Y. 2019. Anti Rituximab Antibody Titer and Therapeutic Response In Non-Hodgkin Lymphoma Patient Receiving R-CHOP Treatment. *The New Armenian Medical Journal*. 13(1) :91-96
- Yasmeen, T., Ali, J., Khan, K., & Siddiqui, N. 2019. Frequency and Causes of Anemia in Lymphoma Patients. *Pakistan Journal of Medical Sciences*, 35(1):61-65.